Global RNA Therapeutics Market – Industry Trends and Forecast to 2031

Get Exclusive Sample PDF of this Report Here

RNA Therapeutics Market Analysis and Size

The RNA therapeutics market is experiencing robust growth globally, with North America leading the market due to increased research activities and substantial funding availability. The market is driven by the rising prevalence of chronic diseases, such as cancer, genetic disorders, and infectious diseases, for which RNA-based therapies show promising results. In addition, advancements in RNA technology, including mRNA and siRNA, have expanded the potential applications of RNA therapeutics, driving market growth.

The global RNA therapeutics market size was valued at USD 6.23 billion in 2023 and is projected to reach USD 16.80 billion by 2031, with a CAGR of 13.20% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Get Exclusive Sample PDF of this Report Here

Market Definition

RNA therapeutics refers to a class of pharmaceuticals that use ribonucleic acid (RNA) molecules to treat diseases by targeting specific genes or proteins. RNA therapeutics can be divided into several categories, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs). mRNA therapeutics are designed to deliver genetic instructions to cells, enabling them to produce proteins that can treat or prevent disease.            

RNA Therapeutics Market Dynamics

Drivers

• Advancements in RNA Technology 

The field of RNA therapeutics has witnessed significant advancements, particularly in the development of messenger RNA (mRNA) and small interfering RNA (siRNA) technologies. The mRNA technology, for instance, has revolutionized vaccine development, as demonstrated by the rapid development of mRNA COVID-19 vaccines. This technology can also be utilized for protein replacement therapies, where mRNA is used to instruct cells to produce missing or defective proteins, offering a promising approach for treating genetic disorders and other diseases. These advancements in RNA technology are expanding the possibilities for RNA therapeutics, making them more precise, effective, and versatile, thus driving market growth.             

• Increasing Prevalence of Chronic Diseases

Chronic diseases, including cancer, genetic disorders, and infectious diseases, are becoming increasingly prevalent worldwide, leading to a growing demand for innovative treatment options. RNA therapeutics offer a promising solution, as they can target specific genes or proteins involved in disease pathways, providing a more targeted and potentially more effective approach compared to traditional treatments. As the burden of chronic diseases continues to rise, the demand for novel and effective therapies such as RNA therapeutics, is expected to drive market growth.

Opportunities

• Advancements in Drug Delivery Systems

The field of drug delivery systems has seen significant advancements, particularly in the context of RNA therapeutics. Nanoparticle-based delivery systems offer a promising approach to deliver RNA molecules to target cells with improved efficacy and reduced side effects. Lipid-based formulations, on the other hand, can improve the stability and bioavailability of RNA therapeutics, enhancing their therapeutic potential. These advancements in drug delivery systems are not only improving the efficacy and safety of RNA therapeutics but are also expanding the possibilities for their application in various diseases, which opens up new opportunities for market growth.           

• Gene Editing Technologies

The development of gene editing technologies, such as CRISPR-Cas9, has revolutionized the field of RNA therapeutics by enabling precise and targeted modifications to the genome. CRISPR-Cas9 technology can be used to edit genes responsible for disease or to silence disease-causing genes, offering potential cures for genetic disorders and other diseases. These advancements in gene editing technologies are creating new opportunities for market growth in the RNA therapeutics field as the potential for innovative and targeted therapies continues to expand.

Restraints/Challenges

• Off-Target Effects   

Off-target effects are the effects where the therapeutic RNA molecules may interact with unintended targets in the body, leading to unintended consequences and safety concerns. These off-target effects can result in adverse reactions and limit the efficacy of RNA therapeutics, which could hinder their adoption and market growth. Researchers are actively striving to reduce off-target effects by enhancing RNA design and delivery systems and by gaining a deeper understanding of RNA biology and its interactions within the body. These Off-target effects are a major challenge for the market growth.            

• High Development Costs 

The development of RNA therapeutics involves significant costs, including research and development expenses, preclinical and clinical trials, and regulatory approvals. These costs can be prohibitively high, especially for small biotechnology companies and startups, which could hinder their ability to bring RNA therapeutics to market. In addition, the lengthy and complex regulatory approval process for RNA therapeutics can further contribute to the high development costs and delays in market entry.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In January 2024, Circular Genomics secured USD 8.3 million in a Series A funding round to launch the world's first circRNA-based clinical assay. This assay aims to enhance depression treatment by predicting patient responses to antidepressants, thereby improving patient care and addressing concerns regarding therapy effectiveness and low clinical outcomes
• In February 2023, Tevard Biosciences partnered with Vertex Pharmaceuticals to develop novel tRNA-based therapies for Duchenne Muscular Dystrophy through a research and development agreement
• In January 2023, Esperovax collaborated with Gingko Bioworks to develop circular RNA therapeutics targeting colorectal cancer under a product development agreement

RNA Therapeutics Market Scope

The market is segmented on the basis of type of modality, type of molecule, therapeutic area, application, route of administration, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type of Modality

• Therapeutics
• Vaccines

 Type of Molecule

• Replicating RNA (repRNA)
• Self Amplifying RNA (saRNA)
• Self Activating RNA (sacRNA)
• Self Activating mRNA (samRNA)
• Transfer RNA (tRNA)

 Therapeutic Area

• Infectious Diseases
• Oncological Disorders
• Pulmonary Disorders

 Application    

• Genetic Disorders
• Auto immune disorders

 Route of Administration

• Intradermal
• Intramuscular
• Intravenous

 End User      

• Research Institutes
• Hospitals & Clinics

RNA Therapeutics Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, type of modality, type of molecule, therapeutic area, application, route of administration, and end user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate and witness significant growth during the forecast period due to the significant increase in research activities focusing on RNA-based treatments and the availability of substantial research funding. The region's dominance is expected to continue as government initiatives further promote the development and adoption of RNA therapeutics. These initiatives, aimed at advancing RNA-based treatments, are projected to drive market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and RNA Therapeutics Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Quark Software Inc. (U.S.)
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Dicerna Pharmaceuticals, Inc. (U.S.)
• Tekmira Pharmaceuticals (Canada)
• Arbutus Biopharma (Canada)
• Benitec Biopharma (Australia)
• Sanofi (France)
• Ionis Pharmaceuticals (U.S.)
• Silence Therapeutics (U.K.)
• Cenix BioScience (Germany)
• Sirnaomics (U.S.)
• CureVac SE (Germany)
• BioNTech SE (Germany)
• Arrowhead Pharmaceuticals, Inc. (U.S.)
• Adhera Therapeutics (U.S.)
• Marina Biotech, Inc. (U.S.)

SKU-51841